A New Treatment For Improving The Use Of Dietary Sugar For Energy Purposes

Abstract

A method comprising, receiving digital-electrical input symbols of a stream of input symbols, the input symbols corresponding to signal points of a symbol constellation. The method also comprises classifying the input symbols, wherein a first symbol class comprises input symbols corresponding to signal points that are variant to rotation of the symbol constellation, and, a second symbol class comprises input symbols corresponding to signal points that are invariant to rotation of the symbol constellation. The method also comprises applying selective differential coding only to those input symbols of the first symbol class.

1 . An oral dosage form of abscisic acid (ABA) or of an in vivo hydrolysable ABA-conjugate, for use in a therapeutic, control or prevention treatment of hyperglycemia without a substantial increase in insulinemia, wherein said dosage form is adapted for the oral administration of ABA or ABA-conjugate at a daily dose comprised between 0.45 μg and 11.4 mg, between 1.5 μg and 6 mg, and between 3 μg and 1.2 mg. 
     
     
         2 . The oral dosage form according to  claim 1 , wherein said abscisic acid (ABA) or ABA-conjugate is contained in a plant extract. 
     
     
         3 . The oral dosage form according to  claim 1 , wherein said ABA-conjugate is hydrolysable in vivo by hydrolysis of an anhydride, ester or amide bond. 
     
     
         4 . The oral dosage form according to  claim 3 , wherein said in vivo hydrolysable ABA-conjugate is a conjugate of ABA with a compound selected from the group consisting of organic acids, inorganic acids, primary alcohols, secondary alcohols, tertiary alcohols, monosaccharides, disaccharides, polysaccharides, biogenic amines and amino acids. 
     
     
         5 . The oral dosage form according to  claim 4 , wherein said in vivo hydrolysable ABA-conjugate is ABA-glucosyl ester (ABA-GE). 
     
     
         6 . A food product comprising an oral dosage form according to  claim 1 , optionally in combination with one or more further organic and/or inorganic substances, said product being preferably selected from the group consisting of carbohydrate-containing human or animal food, healthy products, supplements, sugar-containing energizing beverages, nutraceutical compositions. 
     
     
         7 . Abscisic acid (ABA) or an in vivo hydrolysable ABA-conjugate, for use in a therapeutic, control or prevention treatment of hyperglycemia without a substantial increase in insulinemia, wherein said treatment comprises the oral administration to a subject of an effective amount of abscisic acid (ABA) or ABA-conjugate at a dose comprised between 0.15 and 95 μg/die per Kg of body weight of the subject, between 0.5 and 50 μg/die per Kg of body weight of the subject, and between 1 and 10 μg/die per Kg of body weight of the subject. 
     
     
         8 . Abscisic acid (ABA) or an in vivo hydrolysable ABA-conjugate for use according to  claim 7 , wherein the subject is a human or an animal and is preferably a healthy, diabetic or pre-diabetic subject. 
     
     
         9 . Abscisic acid (ABA) or an in vivo hydrolysable ABA-conjugate for use according to  claim 7 , wherein said therapeutic, control or prevention treatment of hyperglycemia comprises one or more of the following:
 improving glucose tolerance without increasing insulin secretion;   improving muscle performance and/or endurance;   reducing insulin secretion in response to glucose intake;   reducing insulin-dependent triglycerides synthesis and accumulation thereof, with a resulting improved weight control after carbohydrate intake.   
     
     
         10 . Abscisic acid (ABA) or an in vivo hydrolysable ABA-conjugate for use in a therapeutic, control or prevention treatment of hyperglycemia without a substantial increase in insulinemia,
 wherein said ABA-conjugate comprises an oral dosage form of abscisic acid (ABA) or of an in vivo hydrolysable ABA-conjugate, wherein said dosage form is adapted for the oral administration of ABA or ABA-conjugate at a daily dose comprised between 0.45 μg and 11.4 mg, between 1.5 μg and 6 mg, and between 3 μg and 1.2 mg.   
     
     
         11 . The use of an effective dose of ABA and/or an in vivo hydrolysable ABA-conjugate, said effective dose being comprised between 0.45 μg and 11.4 mg, preferably between 1.5 μg and 6 mg, more preferably between 3 μg and 1.2 mg, in the preparation of a product as defined in  claim 7 . 
     
     
         12 . The use according to  claim 11 , wherein said ABA-conjugate comprises an oral dosage form of abscisic acid (ABA) or of an in vivo hydrolysable ABA-conjugate, wherein said dosage form is adapted for the oral administration of ABA or ABA-conjugate at a daily dose comprised between 0.45 μg and 11.4 mg, between 1.5 μg and 6 mg, and between 3 μg and 1.2 mg.